V
VBS
vs
S
S&P/ASX 300
Over the past 12 months, VBS has significantly outperformed S&P/ASX 300, delivering a return of +81% compared to the S&P/ASX 300's +4% growth.
Stocks Performance
VBS vs S&P/ASX 300
Performance Gap
VBS vs S&P/ASX 300
Performance By Year
VBS vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vectus Biosystems Ltd
Glance View
Vectus Biosystems Ltd. operates as a drug discovery and development company. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm has developed treatments for fibrosis and high blood pressure, which include treatment for four of the diseases in the fibrotic franchise, namely heart, kidney, liver and lung disease. Its lead compound VB0004, which is aimed at treating the loss of functional tissue to fibrosis or scarring and high blood pressure. The firm has also developed a technology, Accugen for measuring the amount of Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Using its platform technology, the Company has constructed a library of approximately 200 small molecules with varying degrees of anti-hypertensive and anti-fibrotic properties. Accugen is developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions.
